Evidence map›Paper›PMID 41811068›Full record

ArticleMicrobiology spectrum2026

John Domagala, Seyedhameneh Jahanbakhsh, Angela K Mendez, Chris M Pillar, Andrea Marra, David A Hufnagel, Nora M R Molasky, Zhongsheng Zhang, Erkang Fan, Dawn Reyna and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

John DomagalaTSRL Inc., Ann Arbor, Michigan, USA.
Seyedhameneh JahanbakhshMicrobiologics, Inc., Bacteriology and Mycology Center of Excellence, Portage, Michigan, USA.
Angela K MendezMicrobiologics, Inc., Bacteriology and Mycology Center of Excellence, Portage, Michigan, USA.
Chris M PillarMicrobiologics, Inc., Bacteriology and Mycology Center of Excellence, Portage, Michigan, USA.
Andrea MarraMicrobiologics, Inc., Bacteriology and Mycology Center of Excellence, Portage, Michigan, USA.
David A HufnagelMicrobiologics, Inc., Bacteriology and Mycology Center of Excellence, Portage, Michigan, USA.ORCID 0009-0003-4878-1520
Nora M R MolaskyCERID, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Zhongsheng ZhangDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Erkang FanDepartment of Biochemistry, University of Washington, Seattle, Washington, USA.
Dawn ReynaTSRL Inc., Ann Arbor, Michigan, USA.
Elke LipkaTSRL Inc., Ann Arbor, Michigan, USA.
Frederick S BucknerCERID, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.ORCID 0000-0001-7796-6477

Funding

Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.R44AI134190 · NIAID · TSRL, INC. · PI LIPKA, ELKE · 2017 to 2025
$6.0M
Developing methionyl tRNA synthetase inhibitors as therapeutics for Chagas diseaseR01AI152358 · NIAID · UNIVERSITY OF WASHINGTON · PI BUCKNER, FREDERICK SIMMONS, FAN, ERKANG · 2020 to 2023
$3.1M
NIAID NIH HHS R01 AI152358NIAID NIH HHS R44 AI134190NIH HHS R01 AI152358NIH HHS R44 AI134190
6 · The paper itself

Abstract

New antibacterials are still needed to treat serious gram-positive hospital infections, including acute bacterial skin and skin structure infections and bloodstream infections. MRS-2541 is a novel type 1 methionyl-tRNA synthetase inhibitor highly selective for gram-positive bacteria. MRS-2541 was evaluated with multiple comparator antibiotics against a large panel of gram-positive organisms enriched with antibacterial-resistant phenotypes. MRS-2541 was the most potent agent against 45 IMPORTANCE: Infections caused by antibiotic-resistant bacteria are inherently challenging to treat. Poor outcomes, including higher death rates, are associated with infections caused by antibiotic-resistant organisms. As a result, there is an urgent need for new antibiotics, particularly ones that act via novel mechanisms that evade established resistance mechanisms. In this paper, we provide new data about MRS-2541, a preclinical antibiotic that acts by inhibiting the bacterial methionyl-tRNA synthetase. We show that MRS-2541 has potent in vitro activity against diverse strains of

Indexed as

Anti-Bacterial AgentsCross InfectionGram-Positive BacteriaGram-Positive Bacterial InfectionsDrug Resistance, BacterialHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsantibioticsEnterococcusgram-positiveMetRS inhibitorsStaphylococcusStreptococcustRNA synthetase

Identifiers

PMID41811068
PMCPMC13055339

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.